TaiRx

TaiRx Inventory

The Inventory of TaiRx (6580.TWO) as of Oct 17, 2026 is 3.15 M TWD. In the previous year, Inventory was 171,000.00 TWD — a change of 1,740.35% (higher).

Inventory

3.15 MTWD

YoY

1,740.35%

Last updated:

Inventory of TaiRx is 2025 3.15 M TWD. Inventory of TaiRx was 2024 171,000.00 TWD. It decreases by 1,740.35% higher compared to the previous year.

The TaiRx Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2021
0.00 TWD
Jan 1, 2022
18,000.00 TWD
Jan 1, 2023
11,000.00 TWD
Jan 1, 2024
171,000.00 TWD
Jan 1, 2025
3.15 M TWD
The TaiRx Inventory history
YEARInventoryYoY
3.15 MTWD+1,740.35%
171,000.00TWD+1,454.55%
11,000.00TWD-38.89%
18,000.00TWD—
0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

Inventory of TaiRx is 3.15 M TWD in 2025.

Inventory of TaiRx changed from 171,000.00 TWD to 3.15 M TWD, representing a 1,740.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory TaiRx since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's TaiRx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TaiRx

All Key Metrics — TaiRx